drugset / Trial / NCT06275555
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
RandomizedParallel-groupOpen-labelOther
Summary
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
Timeline
- Start
- 2024-06-03
- Primary completion
- 2026-12-31
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bivalirudin | Peptide | 0.02 mg/kg | — |
| Subject | Bivalirudin | Peptide | 0.04 mg/kg | — |
| Subject | Heparin | Other / unclassified | 8 iu/kg | — |
| Subject | Heparin | Other / unclassified | 12 iu/kg | — |
Indications
No indication recorded.